Pre-analytical considerations for minimum residual disease (MRD) detection by NGS

Name: Pre-analytical considerations for minimum residual disease (MRD) detection by NGS
Start: 2026-11-03
End: 2026-11-03

Starts: November 3, 2026
Ends: November 3, 2026
Format: Online
Location: VIRTUAL

About This Event

Dr. Nafiseh Jafari, Chief Science Officer at nRichDX, Travis Reeder, Vice President of Laboratory Operations & R&D at Strata Oncology, Dr. Scott Tomlins, Co-founder & Chief Medical Officer at Strata Oncology, and Dr. Annika Dorn, Agilent Technologies, share the importance of maximizing cfDNA recovery and purity for liquid biopsy applications, particularly in NGS-based MRD testing.